Workflow
Diabetes Care
icon
Search documents
Best Income Stocks to Buy for September 15th
ZACKS· 2025-09-15 13:11
Group 1: Stock Recommendations - Citizens & Northern Corp (CZNC) has seen a 1.1% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days and offers a dividend yield of 5.6%, significantly higher than the industry average of 2.6% [1] - Embecta Corp. (EMBC) has experienced a 4.3% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days, with a dividend yield of 4%, compared to the industry average of 0.0% [2] - First Financial Bancorp (FFBC) has reported a 6.1% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days and has a dividend yield of 3.9%, above the industry average of 2.9% [3]
New Strong Buy Stocks for September 15th
ZACKS· 2025-09-15 10:41
Core Insights - Five stocks have been added to the Zacks Rank 1 (Strong Buy) List, indicating strong potential for investment Group 1: Company Earnings Estimates - Ranger Energy Services (RNGR) has seen a 42.5% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [1] - Stride (LRN) has experienced a 10.6% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [2] - BorgWarner (BWA) has reported an 8.6% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [3] - KT (KT) has seen a 5.3% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [4] - Embecta Corp. (EMBC) has experienced a 4.3% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [4]
Rosen Law Firm Urges Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
Businesswire· 2025-09-11 17:00
Core Viewpoint - Rosen Law Firm has announced a class action lawsuit against Unicycive Therapeutics, Inc. (NASDAQ: UNCY) on behalf of shareholders who purchased securities during the specified class period, alleging that the company misled investors regarding its business operations [1][2]. Group 1: Allegations and Misleading Statements - The lawsuit claims that Unicycive overstated its readiness to meet FDA manufacturing compliance requirements [3]. - It is alleged that the regulatory prospects of the oxylanthanum carbunate (OLC) New Drug Application (NDA) were also overstated [3]. - As a result of these misleading statements, investors reportedly suffered damages when the true details became public [3]. Group 2: Class Action Participation - Shareholders interested in serving as lead plaintiffs must file their motions with the court by October 14, 2025 [4]. - Participation in the class action is not required to be eligible for recovery; shareholders can remain absent class members if they choose [4]. Group 3: Rosen Law Firm Overview - Rosen Law Firm is recognized for its commitment to shareholder rights litigation and has recovered over $1 billion for shareholders since its inception [6].
Embecta to host Analyst and Investor Day on May 22, 2025
Globenewswire· 2025-04-28 11:30
Core Insights - Embecta Corp. will hold an Analyst and Investor Day on May 22, 2025, in New York City, focusing on strategic and business overview [1][2] - The event will feature presentations from the CEO, CFO, and other leadership team members, discussing value creation opportunities and the company's financial profile [2] - The webcast will be available for registration, and materials will be accessible post-event on the company's Investor Relations website [3] Company Overview - Embecta is a global diabetes care company with a 100-year legacy in insulin delivery, aiming to empower individuals with diabetes through innovative solutions [4] - The company employs approximately 2,000 individuals worldwide, emphasizing partnerships and a commitment to improving the lives of people with diabetes [4]
embecta to Report Fiscal Second Quarter 2025 Financial Results
Newsfilter· 2025-04-21 21:00
Core Viewpoint - Embecta Corp. will host a conference call to discuss its fiscal second quarter 2025 financial results and provide an operational update on May 9, 2025 [1] Group 1: Conference Call Details - The conference call is scheduled for 8:00 a.m. Eastern Time (ET) [1] - Participants can access the live webcast through the company's website or via a teleconference link [2] - A replay of the call will be available starting at 11:00 a.m. ET on the same day and will be archived for one year [2] Group 2: Company Overview - Embecta is a global diabetes care company with a 100-year legacy in insulin delivery [3] - The company aims to empower people with diabetes through innovative solutions and partnerships, supported by approximately 2,000 employees worldwide [3]